Literature DB >> 22650381

Management of cluster headache.

Peer C Tfelt-Hansen1, Rigmor H Jensen.   

Abstract

The prevalence of cluster headache is 0.1% and cluster headache is often not diagnosed or misdiagnosed as migraine or sinusitis. In cluster headache there is often a considerable diagnostic delay - an average of 7 years in a population-based survey. Cluster headache is characterized by very severe or severe orbital or periorbital pain with a duration of 15-180 minutes. The cluster headache attacks are accompanied by characteristic associated unilateral symptoms such as tearing, nasal congestion and/or rhinorrhoea, eyelid oedema, miosis and/or ptosis. In addition, there is a sense of restlessness and agitation. Patients may have up to eight attacks per day. Episodic cluster headache (ECH) occurs in clusters of weeks to months duration, whereas chronic cluster headache (CCH) attacks occur for more than 1 year without remissions. Management of cluster headache is divided into acute attack treatment and prophylactic treatment. In ECH and CCH the attacks can be treated with oxygen (12 L/min) or subcutaneous sumatriptan 6 mg. For both oxygen and sumatriptan there are two randomized, placebo-controlled trials demonstrating efficacy. In both ECH and CCH, verapamil is the prophylactic drug of choice. Verapamil 360 mg/day was found to be superior to placebo in one clinical trial. In clinical practice, daily doses of 480-720 mg are mostly used. Thus, the dose of verapamil used in cluster headache treatment may be double the dose used in cardiology, and with the higher doses the PR interval should be checked with an ECG. At the start of a cluster, transitional preventive treatment such as corticosteroids or greater occipital nerve blockade can be given. In CCH and in long-standing clusters of ECH, lithium, methysergide, topiramate, valproic acid and ergotamine tartrate can be used as add-on prophylactic treatment. In drug-resistant CCH, neuromodulation with either occipital nerve stimulation or deep brain stimulation of the hypothalamus is an alternative treatment strategy. For most cluster headache patients there are fairly good treatment options both for acute attacks and for prophylaxis. The big problem is the diagnosis of cluster headache as demonstrated by the diagnostic delay of 7 years. However, the relatively short-lasting attack of pain in one eye with typical associated symptoms should lead the family doctor to suspect cluster headache resulting in a referral to a neurologist or a headache centre with experience in the treatment of cluster headache.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22650381     DOI: 10.2165/11632850-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  47 in total

Review 1.  Cluster headache--acute and prophylactic therapy.

Authors:  Avi Ashkenazi; Todd Schwedt
Journal:  Headache       Date:  2011-02       Impact factor: 5.887

2.  Treatment of acute cluster headache with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  Occipital nerve stimulation for intractable cluster headache.

Authors:  Anna Ambrosini
Journal:  Lancet       Date:  2007-03-31       Impact factor: 79.321

4.  Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo.

Authors:  M Leone; D D'Amico; F Frediani; F Moschiano; L Grazzi; A Attanasio; G Bussone
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

Review 5.  Cluster headache: pathogenesis, diagnosis, and management.

Authors:  Arne May
Journal:  Lancet       Date:  2005 Sep 3-9       Impact factor: 79.321

6.  Invasive adenoma of the pituitary gland and chronic migrainous neuralgia. A rare coincidence or a causal relationship?

Authors:  P Tfelt-Hansen; O B Paulson; A A Krabbe
Journal:  Cephalalgia       Date:  1982-03       Impact factor: 6.292

Review 7.  Evidence base for the medical treatments used in cluster headache.

Authors:  Alok Tyagi; Manjit Matharu
Journal:  Curr Pain Headache Rep       Date:  2009-04

8.  Burden of cluster headache.

Authors:  R M Jensen; A Lyngberg; R H Jensen
Journal:  Cephalalgia       Date:  2007-04-25       Impact factor: 6.292

9.  Hyperbaric oxygen therapy in cluster headache.

Authors:  Francesco Di Sabato; Bruno M Fusco; Paolo Pelaia; Mario Giacovazzo
Journal:  Pain       Date:  1993-02       Impact factor: 6.961

10.  Hypothalamic deep-brain stimulation: target and potential mechanism for the treatment of cluster headache.

Authors:  A May
Journal:  Cephalalgia       Date:  2008-07       Impact factor: 6.292

View more
  6 in total

Review 1.  Pain and suicidality: insights from reward and addiction neuroscience.

Authors:  Igor Elman; David Borsook; Nora D Volkow
Journal:  Prog Neurobiol       Date:  2013-07-01       Impact factor: 11.685

Review 2.  Occipital injections for trigemino-autonomic cephalalgias: evidence and uncertainties.

Authors:  Elizabeth Leroux; Anne Ducros
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 3.  Triptans for acute cluster headache.

Authors:  Simon Law; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

4.  The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1.

Authors:  Lasse Saaby; Peer Tfelt-Hansen; Birger Brodin
Journal:  Pharmacol Res Perspect       Date:  2015-06-11

5.  Patient satisfaction with conventional, complementary, and alternative treatment for cluster headache in a Norwegian cohort.

Authors:  Svein I Bekkelund; Hilde K Ofte; Karl B Alstadhaug
Journal:  Scand J Prim Health Care       Date:  2014-08-13       Impact factor: 2.581

Review 6.  Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.

Authors:  Naila Qayyum; Muhammad Haseeb; Moon Suk Kim; Sangdun Choi
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.